Study S000557

Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and Albuminuria - A Double Blinded, Randomised, Placebo Controlled, Parallel, Single Center Study

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT04061200
Acronym: EmpaSema
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: QUADRUPLE
Status: UNKNOWN
Enrollment: 80
Start: 2019-11-01
Primary completion: 2021-07-01
Lead sponsor: Steno Diabetes Center Copenhagen
Conditions: Type 2 Diabetes With Renal Manifestations
Interventions: DRUG:Semaglutide, 1.34 mg/mL; OTHER:Placebo, 1,34 mg/mL; DRUG:Empagliflozin 25 MG
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: NIH:2019

Registered primary outcomes

Albuminuria [From randomisation to week 52]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0010237	Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes. Natale P, The Cochrane database of systematic reviews	2025	Systematic review	PMID 39963952 DOI	cites ClinicalTrials.gov:NCT04061200; registry reference DERIVED:39963952
R0013631	Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes. Natale P, The Cochrane database of systematic reviews	2024	Systematic review	PMID 38770818 DOI	cites ClinicalTrials.gov:NCT04061200; registry reference DERIVED:38770818